India Today on MSN12 小时
US FDA approves new nasal spray for depression treatment: All about it
The company said that the nasal spray is a ketamine-derived drug, first approved in 2019, to be used in combination with ...
Nose spray to treat depression? FDA approves first-of-its-kind medicine
The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.
How the brain learns from rewards might hold the key to personalized depression treatment
A brain signal that lights up when we anticipate rewards may hold the secret to helping people overcome depression, and ...
FDA Approves Nasal Spray for Depression
The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
Why a common asthma drug will now carry extra safety warnings about depression
The TGA has issued a requirement for new warnings to be provided with the drug montelukast, commonly used to treat asthma and ...
Healio8 小时
FDA approves Spravato as monotherapy for adults with major depressive disorder
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
Neuroscience News4 小时
Targeting Reward Pathways to Treat Depression
New research highlights how the brain's reward-learning system can guide personalized treatments for depression.
NJBIZ7 小时
J&J’s ketamine-based drug approved as standalone treatment
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...
The FDA just approved this ketamine-derived nasal spray for depression treatment
The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...
FDA approves Spravato, first monotherapy nasal spray to treat depression
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
GlobalData on MSN12 小时
J&J’s Spravato receives FDA label expansion for depression monotherapy
Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...